Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world.

Fang, Min; Hang, Qingqing; Jiang, Haitao; Cai, Lei; Hu, Jinlin; Ying, Hangjie; Gu, Qing; Yu, Xiaofu; Liu, Jinshi; Lai, Xiaojing

Fang, Min; Hang, Qingqing; Jiang, Haitao; Cai, Lei; Hu, Jinlin; Ying, Hangjie; Gu, Qing; Yu, Xiaofu; Liu, Jinshi; Lai, Xiaojing.

Afiliación

Fang M; Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, China.
Hang Q; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Jiang H; Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, China.
Cai L; The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Hu J; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Ying H; Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, China.
Gu Q; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Yu X; Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
Liu J; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Lai X; Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, China.

Front Oncol ; 12: 1055610, 2022.

Article en En | MEDLINE | ID: mdl-36713546

Palabras clave

NSCLC; chemotherapy; immunotherapy; neoadjuvant; surgery

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google